Download PDF
Planta Med 2020; 86(04): 276-283
DOI: 10.1055/a-1087-8374
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics, Pharmacodynamics and Dermal Distribution of 5-Methoxypsoralen Based on a Physiologically Based Pharmacokinetic Model to Support Phytotherapy Using Brosimum gaudichaudii

Frederico Severino Martins
1   Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, São Paulo, Brazil
,
Sherwin K.B. Sy
2   Department of Statistics, State University of Maringá, Maringá, Brazil
,
Maria José Vieira Fonseca
1   Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, São Paulo, Brazil
,
Osvaldo de Freitas
1   Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, São Paulo, Brazil
› Author AffiliationsSupported by: Capes and São Paulo Research Foundation – FAPESP grant number 12/15979-0
Further Information

Publication History

received 16 October 2019
revised 28 November 2019

accepted 31 December 2019

Publication Date:
22 January 2020 (online)

    Permissions and Reprints

Abstract

The treatment of vitiligo includes the combination of psoralens and ultraviolet type A exposure. Psoralens belong to a group of natural furanocoumarins that cause the skin to become sensitive temporarily to ultraviolet type A. The aim of this study was to develop a physiologically based pharmacokinetic model of 5-MOP from Brosimum gaudichaudii to support psoralen and ultraviolet type A therapy. A study of rats was used to establish and validate rat tissue distribution. The same chemical-specific parameters used in the rat model were also employed in the human model to project human pharmacokinetics. The highest exposures in the rats were in the brain and skin. Following a single dose of 1.2 mg/kg 5-MOP in humans, the model predicted a maximum concentration of 20 ng/mL and an area under the curve of 125 ng.h/mL, matching clinical results. The half-maximum melanogenesis concentrations in B16F10 cells were 29.5, 18.5, 11.5, and 6.5 ng/mL for synthetic 5-MOP, synthetic 5-MOP with ultraviolet type A, B. gaudichaudii alone, and B. gaudichaudii plus ultraviolet type A, respectively. Physiologically based pharmacokinetic model prediction in humans supported a once-every-two-day regimen for optimal melanin production. This type of framework can be applied to support strategies for dose selection and to investigate the impact of drugs on melanocyte recovery.

Key words

vitiligo - skin - psoralen - PUVA - Brosimum gaudichaudii - Moraceae
 

  • References

  • 1 Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Pediatr Dermatol 2003; 20: 207-210
    CrossrefPubMedGoogle Scholar
  • 2 Gupta V, Sreenivas V, Mehta M, Ramam M. What do Vitiligo Impact Scale-22 scores mean? Studying the clinical interpretation of scores using an anchor-based approach. Br J Dermatol 2019; 180: 580-585
    CrossrefPubMedGoogle Scholar
  • 3 Hill-Beuf A, Porter JD. Children coping with impaired appearance: social and psychologic influences. Gen Hosp Psychiatry 1984; 6: 294-301
    CrossrefPubMedGoogle Scholar
  • 4 Kent G, al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol 1996; 21: 330-333
    CrossrefPubMedGoogle Scholar
  • 5 Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005; 152: 1165-1172
    CrossrefPubMedGoogle Scholar
  • 6 Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Gonzalez S, Westerhof W. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2007; 21: 942-950
    CrossrefPubMedGoogle Scholar
  • 7 Kanwar AJ, Kumaran MS. Childhood vitiligo: treatment paradigms. Indian J Dermatol 2012; 57: 466-474
    CrossrefPubMedGoogle Scholar
  • 8 Shenoi SD, Prabhu S. Indian Association of Dermatologists, Venereologists and Leprologists. Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol Venereol Leprol 2014; 80: 497-504
    CrossrefPubMedGoogle Scholar
  • 9 Calzavara-Pinton PG, Carlino A, Manfredi E, Semeraro F, Zane C, De Panfilis G. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol Suppl (Stockh) 1994; 186: 164-165
    PubMedGoogle Scholar
  • 10 Part 7 – Drug-induced ocular Side Effects. In: Fraunfelder FT, Fraunfelder FW, Chambers WA. eds. Clinical Ocular Toxicology: Drugs, Chemicals and Herbs. Edinburgh: W.B. Saunders; 2008: 45-287
    Google Scholar
  • 11 Cunha LC, Paula JR, Sá VA, Amorim MEP, Barros ICM, Brito LAB, Silveira N. Acute toxicity of Brosimum gaudichaudii Trécul. root extract in mice: determination of both approximate and median lethal doses. Rev Bras Farmacogn 2008; 18: 532-538
    PubMedGoogle Scholar
  • 12 Pozetti GL. Brosimum gaudichaudii Trecul (Moraceae): da planta ao medicamento. Rev Ciênc Farm Básica Apl 2009; 26: 159-166
    PubMedGoogle Scholar
  • 13 Sy SK, Wang X, Derendorf H. Introduction to Pharmacometrics and quantitative Pharmacology with an Emphasis on physiologically based Pharmacokinetics. In: Derendorf H, Schmidt S. eds. Applied Pharmacometrics. New York: Springer; 2014: 1-64
    Google Scholar
  • 14 Eichler HG, Muller M. Drug distribution. The forgotten relative in clinical pharmacokinetics. Clin Pharmacokinet 1998; 34: 95-99
    CrossrefPubMedGoogle Scholar
  • 15 Pozetti GL. [Chemical study of Brosimum gaudichaudii Trecul. 1. Isolation and identification of bergapten, and psoralene from the roots of Brosimum gaudichaudii Trecul]. Rev Fac Farm Odontol Araraquara 1969; 3: 215-223
    PubMedGoogle Scholar
  • 16 Malcov-Brog H, Alpert A, Golan T, Parikh S, Nordlinger A, Netti F, Sheinboim D, Dror I, Thomas L, Cosson C, Gonen P, Stanevsky Y, Brenner R, Perluk T, Frand J, Elgavish S, Nevo Y, Rahat D, Tabach Y, Khaled M, Shen-Orr SS, Levy C. UV-Protection timer controls linkage between stress and pigmentation skin protection systems. Mol Cell 2018; 72: 444-456.e7
    CrossrefPubMedGoogle Scholar
  • 17 Yu XA, Azietaku JT, Li J, An M, He J, Hao J, Cao J, Chang YX. The pharmacokinetics, bioavailability and excretion of bergapten after oral and intravenous administration in rats using high performance liquid chromatography with fluorescence detection. Chem Cent J 2016; 10: 62
    CrossrefPubMedGoogle Scholar
  • 18 Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 2011; 7: 267-286
    CrossrefPubMedGoogle Scholar
  • 19 Aubin F, Makki S, Humbert P, Muret P, Agache P. Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation. Arch Dermatol Res 1994; 286: 30-34
    CrossrefPubMedGoogle Scholar
  • 20 de Wolff FA, Thomas TV. Clinical pharmacokinetics of methoxsalen and other psoralens. Clin Pharmacokinet 1986; 11: 62-75
    CrossrefPubMedGoogle Scholar
  • 21 Ehrsson H, Wallin I, Ros AM, Eksborg S, Berg M. Food-induced increase in bioavailability of 5-methoxypsoralen. Eur J Clin Pharmacol 1994; 46: 375-377
    PubMedGoogle Scholar
  • 22 Martins FS, Pascoa H, de Paula JR, da Conceicao EC. Technical aspects on production of fluid extract from Brosimum gaudichaudii Trecul roots. Pharmacogn Mag 2015; 11: 226-231
    CrossrefPubMedGoogle Scholar
  • 23 Heo SJ, Ko SC, Cha SH, Kang DH, Park HS, Choi YU, Kim D, Jung WK, Jeon YJ. Effect of phlorotannins isolated from Ecklonia cava on melanogenesis and their protective effect against photo-oxidative stress induced by UV-B radiation. Toxicol In Vitro 2009; 23: 1123-1130
    CrossrefPubMedGoogle Scholar
  • 24 Waters NJ, Jones R, Williams G, Sohal B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci 2008; 97: 4586-4595
    CrossrefPubMedGoogle Scholar
  • 25 Evans CA, Jolivette LJ, Nagilla R, Ward KW. Extrapolation of preclinical pharmacokinetics and molecular feature analysis of “discovery-like” molecules to predict human pharmacokinetics. Drug Metab Dispos 2006; 34: 1255-1265
    CrossrefPubMedGoogle Scholar
  • 26 Zucchi A, Raho E, Marconi B, Nicoli S, Santini M, Allegra F, Colombo P, Bettini R, Santi P. Plasma and skin concentration of 5-methoxypsoralen in psoriatic patients after oral administration. J Invest Dermatol 2001; 117: 379-382
    CrossrefPubMedGoogle Scholar
  • 27 Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro 2008; 22: 457-467
    CrossrefPubMedGoogle Scholar
  • 28 Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95: 1238-1257
    CrossrefPubMedGoogle Scholar
  • 29 Sy SK, Malmberg R, Matsushima A, Asin-Prieto E, Rosenkranz B, Cotton MF, Derendorf H, Innes S. Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model. Int J Antimicrob Agents 2015; 45: 413-419
    CrossrefPubMedGoogle Scholar
  • 30 Biesdorf C, Martins FS, Sy SKB, Diniz A. Physiologically-based pharmacokinetics of ziprasidone in pregnant women. Br J Clin Pharmacol 2019; 85: 914-923
    CrossrefPubMedGoogle Scholar